Company news
Esperion Therapeutics, Inc. news in 2020
Esperion Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 14, 2020
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
November 11, 2020
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
November 9, 2020
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
November 1, 2020
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
October 18, 2020
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
September 27, 2020
Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
August 25, 2020
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
August 9, 2020
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
August 2, 2020
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
June 30, 2020
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
June 21, 2020
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
June 13, 2020
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 3, 2020
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
May 5, 2020
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
April 29, 2020
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
April 19, 2020
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 5, 2020
Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
March 29, 2020
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
March 17, 2020
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
February 25, 2020
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
February 20, 2020
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
January 30, 2020
Decks in 2020
- Investor Presentation (April 2020)
Investor deck · 33 slides · Apr 9, 2020